Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.53 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL726313 | 0.85 | IDO1 (0.59) | IDO1CYP3A4KMT2AMEN1CYP1A2 | |
| SCHEMBL7364258 | 0.83 | IDO1 (0.57) | IDO1CYP3A4BAZ2BKMT2AMEN1 | |
| SCHEMBL6601781 | 0.83 | IDO1 (0.57) | IDO1CYP3A4BAZ2BKMT2AMEN1 | |
| SCHEMBL17773146 | 0.83 | IDO1 (0.53) | IDO1CYP3A4BAZ2BKMT2AMEN1 | |
| SCHEMBL7241223 | 0.83 | IDO1 (0.53) | IDO1CYP3A4BAZ2BKMT2AMEN1 | |
| SCHEMBL17773185 | 0.83 | IDO1 (0.53) | IDO1CYP3A4BAZ2BKMT2AMEN1 | |
| SCHEMBL5319526 | 0.83 | IDO1 (0.53) | IDO1CYP3A4BAZ2BKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL10438238 | 0.82 | IDO1 (0.56) | IDO1CYP3A4BAZ2BKMT2AMEN1 | |
| SCHEMBL1239412 | 0.81 | IDO1 (0.54) | IDO1CYP3A4BAZ2BKMT2AMEN1 | |
| SCHEMBL11802077 | 0.81 | CYP19A1 (0.56) | IDO1CYP3A4BAZ2BKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101484453-A | Derivatives of imidazo [1, 2-alpha ] pyridine-2-carboxamides, their preparation and their use in therapy | SANOFI AVENTIS (FR) | 2009-07-15 | — | — | CN | claimed |
| US-20160145251-A1 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2016-05-26 | — | — | US | disclosed |
| WO-2016073847-A2 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-05-12 | — | — | WO | disclosed |
| CN-103492474-A | Rubber composition and pneumatic tire | SUMITOMO RUBBER IND | 2014-01-01 | — | — | CN | disclosed |
| US-8299035-B2 | 10a-azalide compound having 4-membered ring structure | TAISHO PHARMACEUTUCAL CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| CN-101484453-B | Derivatives of imidazo [1, 2-alpha ] pyridine-2-carboxamides, their preparation and their use in therapy | SANOFI AVENTIS | 2012-07-04 | — | — | CN | disclosed |
| US-20110152239-A1 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| EP-2287173-A1 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
| CN-101484453-A | Derivatives of imidazo [1, 2-alpha ] pyridine-2-carboxamides, their preparation and their use in therapy | SANOFI AVENTIS (FR) | 2009-07-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145251-A1 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | SREBF1, SREBF2, BPTF | IDO1 4415/4885CYP3A4 4005/4885BAZ2B 285/4885 |
| US-20110152239-A1 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE | ELOVL3, ELOVL5, SCD5 | IDO1 3310/4885CYP3A4 516/4885BAZ2B 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.